Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
B-cell Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia
BIOLOGICAL: XmAb13676
Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03, Baseline Day 1 through Day 56|Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing, Baseline Day 1 through Day 56
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).